5
503A vs 503B503A and 503B are two sections of the U.S.
503B outsourcing facilityA 503B outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act.
A
A1CA1C is a blood test that shows a person's average blood glucose, or blood sugar, over the past 3 months.
AHIThe apnea-hypopnea index, or AHI, is the number of apneas and hypopneas during an hour of sleep: apneas are pauses in breathing, and hypopneas are sha
AlbiglutideAlbiglutide is a GLP-1 receptor agonist that was injected once a week for type 2 diabetes and sold as Tanzeum, approved by the FDA on April 15, 2014.
AMPLITUDE-OAMPLITUDE-O is the cardiovascular and kidney trial of efpeglenatide, a once-weekly GLP-1 medicine.
AmylinAmylin is a hormone made by the same cells in the pancreas that make insulin, and released together with it after a meal.
ATTAIN-1ATTAIN-1 is the main phase 3 trial of orforglipron, the daily GLP-1 pill later approved as Foundayo.
B
Bone mineral densityBone mineral density, or BMD, is the amount of calcium and other minerals in an area of bone.
BupropionBupropion is an antidepressant used to treat depression and seasonal affective disorder and to help people stop smoking.
C
CagrilintideCagrilintide is an experimental, long-acting copy of the hormone amylin, developed by Novo Nordisk and injected once a week.
CagriSemaCagriSema is an experimental combination from Novo Nordisk of two medicines given together once a week: cagrilintide, a long-acting copy of the hormon
CholelithiasisCholelithiasis is the name doctors sometimes use for gallstones: hard, pebble-like pieces, usually made of cholesterol or bilirubin, that form in the
Compounded GLP-1A compounded GLP-1 is a version of semaglutide or tirzepatide made by a compounding pharmacy or an outsourcing facility rather than by the drug's make
ContraveContrave is a weight-management tablet that combines two older medicines: naltrexone, an opioid antagonist, and bupropion, an antidepressant.
D
Dual agonistA dual agonist is a single molecule that activates two different hormone receptors.
DulaglutideDulaglutide is a GLP-1 receptor agonist injected once a week, sold by Eli Lilly as Trulicity and first approved in the United States in 2014.
E
EcnoglutideEcnoglutide is a once-weekly GLP-1 receptor agonist developed by Sciwind Biosciences.
eGFReGFR, the estimated glomerular filtration rate, is a number that shows how well the kidneys are filtering blood.
ELIXAELIXA is the cardiovascular trial of lixisenatide, a short-acting GLP-1 medicine injected once a day.
ExenatideExenatide is a GLP-1 receptor agonist first approved in the United States in 2005, under the brand name Byetta, to improve blood sugar control in adul
EXSCELEXSCEL is the cardiovascular trial of extended-release exenatide, a once-weekly form of the first GLP-1 medicine.
F
FAERSFAERS, the FDA Adverse Event Reporting System, is FDA's database of reports of adverse events, medication errors and quality complaints that led to ad
FDA drug shortage listThe FDA drug shortage list, kept in FDA's Drug Shortage Database, records drugs whose supply in the United States does not meet demand, along with res
FLOWFLOW is the trial that showed semaglutide slows kidney disease in people with type 2 diabetes.
Food noiseFood noise is a popular name for persistent thoughts about food and preoccupation with it.
FoundayoFoundayo is the brand name of orforglipron, a once-daily tablet made by Eli Lilly and approved in the United States in 2026 for weight management.
G
Gastric emptyingGastric emptying is the movement of food from the stomach into the small intestine, and its rate is how fast that happens.
GastroparesisGastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from the stomach to the small intestine.
GIP receptorThe GIP receptor is the protein that responds to glucose-dependent insulinotropic polypeptide, or GIP, one of the two gut hormones that make the pancr
GLP-1 medicines and anesthesiaGLP-1 medicines slow the emptying of the stomach, so food can still be there at the time of surgery or deep sedation even after the usual fasting.
GLP-1 medicines and pregnancyGLP-1 medicines are not used during pregnancy for weight loss.
GLP-1 receptorThe GLP-1 receptor is a protein on the surface of certain cells that responds to glucagon-like peptide-1, a hormone released by the gut after eating.
H
Half-lifeThe half-life of a medicine is the time it takes for its level in the blood to fall by half.
Harmony OutcomesHarmony Outcomes is the cardiovascular trial of albiglutide, a weekly GLP-1 medicine once sold as Tanzeum.
I
IleusIleus is a condition in which the bowel stops working correctly even though nothing is physically blocking it.
Intensive behavioral therapy (IBT)Intensive behavioral therapy, or IBT, for obesity is a Medicare Part B preventive benefit.
K
L
LEADERLEADER is the cardiovascular trial of liraglutide, the GLP-1 medicine sold as Victoza for type 2 diabetes.
Lean mass lossLean mass is everything in the body that is not fat or bone mineral, as a DXA body scan sorts it: muscle plus other tissue that is not fat.
LiraglutideLiraglutide is a GLP-1 receptor agonist injected once a day, made by Novo Nordisk and first approved in the United States in 2010.
M
MACEMACE stands for major adverse cardiovascular events.
MariTideMariTide is the working name of maridebart cafraglutide, an experimental obesity medicine from Amgen.
MASLD and MASHMASLD, metabolic dysfunction-associated steatotic liver disease, is the name chosen in 2023 for what used to be called nonalcoholic fatty liver diseas
MazdutideMazdutide is a weekly injection from Innovent Biologics that activates two receptors, those for GLP-1 and for glucagon.
Medullary thyroid carcinoma (MTC)Medullary thyroid carcinoma, or MTC, is a cancer of the thyroid gland that starts in the C cells, the cells that release the hormone calcitonin.
Missed doseA missed dose is a scheduled dose of a medicine that was not taken on time.
MounjaroMounjaro is a brand of tirzepatide, a once-weekly injection made by Eli Lilly and approved in the United States in 2022 to improve blood sugar control
N
NaltrexoneNaltrexone is a medicine that blocks the effects of opioids.
Non-peptide GLP-1 agonistA non-peptide GLP-1 agonist is a medicine that activates the GLP-1 receptor without being a peptide, the chain of amino acids that every earlier GLP-1
O
Off-label useOff-label use is the use of an FDA-approved drug in a way FDA has not approved.
OrforglipronOrforglipron is a GLP-1 receptor agonist that is not a peptide: a small molecule, taken by mouth once a day, that activates the same receptor as semag
OzempicOzempic is a brand of semaglutide made by Novo Nordisk, best known as a once-weekly injection approved in the United States in 2017 to improve blood s
P
Pancreatic cancer riskPancreatic cancer risk is one of the long-standing questions about GLP-1 medicines.
PancreatitisPancreatitis is inflammation of the pancreas, the gland behind the stomach that makes insulin and the enzymes that digest food; it happens when those
PemvidutidePemvidutide is an experimental weekly injection from Altimmune that activates two receptors, GLP-1 and glucagon, the same pairing as survodutide and m
PhenterminePhentermine is a prescription appetite suppressant, chemically related to amphetamine, approved as a short-term aid to weight loss lasting a few weeks
PIONEER 6PIONEER 6 is the cardiovascular safety trial of oral semaglutide, the daily tablet later sold as Rybelsus.
PlateauA weight-loss plateau is the point at which weight stops falling, or falls so slowly that it seems to have stopped.
Prior authorizationPrior authorization is approval from a health plan that may be required before a person gets a service or fills a prescription, for the plan to cover
Q
R
Rebound weight gainRebound weight gain is the weight that comes back after a weight-loss medicine is stopped.
RetatrutideRetatrutide is an experimental weekly injection from Eli Lilly that activates three hormone receptors at once: those for GIP, GLP-1 and glucagon.
REWINDREWIND is the cardiovascular trial of dulaglutide, the weekly GLP-1 medicine sold as Trulicity.
RybelsusRybelsus is a brand of semaglutide taken as a tablet once a day, made by Novo Nordisk for adults with type 2 diabetes.
S
SarcopeniaSarcopenia is a muscle disease, or muscle failure, rooted in harmful changes in muscle that build up over a lifetime.
SaxendaSaxenda is a brand of liraglutide, a once-daily injection made by Novo Nordisk for weight management.
SCALE DiabetesSCALE Diabetes is the trial of liraglutide 3.0 mg, the dose later sold as Saxenda, for weight in people with type 2 diabetes.
SCALE MaintenanceSCALE Maintenance tested whether liraglutide 3.0 mg, the dose sold as Saxenda, helps keep off weight lost by dieting.
SELECTSELECT is the trial that showed semaglutide lowers heart risk in people with excess weight who do not have diabetes.
SemaglutideSemaglutide is a lab-made version of the gut hormone GLP-1, changed so that it lasts about a week in the body.
SNACSNAC, short for salcaprozate sodium, is an absorption enhancer: an inactive ingredient that helps another drug get into the body.
STEP 1STEP 1 is the main trial behind the approval of Wegovy for weight management.
STEP 2STEP 2 is the trial of semaglutide for weight in people with type 2 diabetes.
STEP 4STEP 4 is the trial that tested what happens when semaglutide is stopped.
STEP TEENSSTEP TEENS is the trial that led to the approval of Wegovy for adolescents.
STEP-HFpEFSTEP-HFpEF is the trial of semaglutide in people with obesity and heart failure with preserved ejection fraction, a form of heart failure in which the
Subcutaneous injectionA subcutaneous injection, often written SQ or sub-Q, is a shot given into the fatty tissue just under the skin, rather than into a muscle or a vein.1
SUMMITSUMMIT is the trial of tirzepatide in people with obesity and heart failure with preserved ejection fraction, the form of heart failure in which the h
SURMOUNT-1SURMOUNT-1 is the main trial behind the approval of Zepbound for weight management.
SURMOUNT-2SURMOUNT-2 is the trial of tirzepatide for weight in people with type 2 diabetes.
SURMOUNT-3SURMOUNT-3 tested whether tirzepatide adds to weight already lost through diet and exercise.
SURMOUNT-5SURMOUNT-5 is the trial that compared tirzepatide, the drug in Zepbound, directly with semaglutide, the drug in Wegovy, for weight management.
SURMOUNT-OSASURMOUNT-OSA is a pair of trials that tested tirzepatide for obstructive sleep apnea in adults with obesity.
SURPASS-2SURPASS-2 is the trial that put tirzepatide head to head with semaglutide in type 2 diabetes.
SurvodutideSurvodutide is an experimental weekly injection from Boehringer Ingelheim that activates two receptors, those for glucagon and for GLP-1, which makes
SUSTAIN 6SUSTAIN 6 is the cardiovascular trial of semaglutide in people with type 2 diabetes, the trial behind Ozempic's heart indication.
SwitchingSwitching means moving from one GLP-1 medicine to another, or from one form of the same medicine to another, such as from a weekly injection to a dail
SYNERGY-NASHSYNERGY-NASH is a phase 2 trial of tirzepatide in metabolic dysfunction-associated steatohepatitis, or MASH, the inflammatory form of fatty liver dise
T
TachyphylaxisTachyphylaxis is the weakening of a drug's effect with repeated doses.
Telogen effluviumTelogen effluvium is diffuse hair shedding that starts two to three months after a triggering event, such as fast weight loss.
TirzepatideTirzepatide is a lab-made peptide that activates the receptors of two gut hormones, GIP and GLP-1, which is why it is often called a dual agonist.
TitrationTitration means starting a medicine at a low dose and raising it in steps until the dose that will be kept, called the maintenance dose.
TopiramateTopiramate is an anticonvulsant used to treat certain types of seizures and to prevent migraine headaches.
Total body weight loss (TBWL)Total body weight loss, or TBWL, is the weight a person has lost as a percentage of their starting weight: the starting weight minus the current weigh
Triple agonistA triple agonist is a single molecule that activates three hormone receptors at once.
V
W
WashoutA washout, or washout period, is a planned stretch of time without a medicine before something else starts: another medicine, a trial or a test.
WegovyWegovy is a brand of semaglutide made by Novo Nordisk for weight management, sold as a once-weekly injection and as a once-daily tablet.
Z
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider